An agile CRO for complex clinical studies

Say hello to a responsive, specialist, flexible approach

We are Simbec-Orion, who for the last four decades, have been providing clinical trial management services across a wide range of therapeutic indications and phases. The clinical research organisation with a flexible, specialist approach, we strive to become a trusted partner for our clients. Our passion as a CRO is rare diseases and oncology.

Our experience defines our expertise

Responding to the evolving needs of our clients has made us the contract research organisation we are today. Offering a full-service clinical development portfolio, but with the size, agility, and structure to respond rapidly when needed. With a team of experienced management, clinical research and scientific advisory specialists, we deliver precise clinical development solutions with expertise.

From First-in-Human phase I, including a full range of late-phase clinical pharmacology studies, through to phase III rescue studies, central laboratory services, and post-marketing, we are the CRO ready to take on the challenge. Whatever the indication or compound you are passionate about, wherever you are in your clinical development journey, we will act as an extension of your team to manage every element of your clinical trial.

A closer look at our expertise

Clinical Pharmacology

We have the expertise and facilities to deliver exceptional clinical services, with a full-service unit dedicated to clinical pharmacology. We perform a range of pharmacology studies , including First-in-Human (FIH) , food effect, drug-drug interaction and pharmacokinetic studies, at our dedicated Clinical Pharmacology Unit. Our facility also includes an Investigational Medicinal Product management capability as well as an on site Bioanalytical and Clinical Pathology Laboratory service, enabling rapid turnaround times and eliminating sample shipment costs.

With over 45 years of operation, we are one of the most experienced contract research organisations in the UK, having successfully delivered over 2000 Phase I/IIa studies in a wide range of therapeutic indications and routes of administration.

Discover clinical pharmacology

Clinical Development Solutions

We are a CRO with in-depth experience of the most challenging therapeutic areas including oncology, rare and orphan diseases, respiratory, dermatology, vaccines and anti-infectives.

With more than 25 years’ experience in the sector, we offer a comprehensive service you can trust – with an international reach. All with the highest level of quality, agility, and responsive customer service.

Explore clinical development services

Central Laboratory Services

Simbec-Orion Full Service Solutions provide central laboratory analyses for Phase IIII trials. These services are designed exclusively for the biotech pharmaceutical industry.

Our combined expertise, experience and investment in infrastructure enables us to provide a rapid, responsible, and reliable service, so you can make critical decisions, fast.

View central laboratory services

Therapy areas in detail

The clinical research organisation with wide therapeutic experience, specialising in rare disease and oncology clinical development solutions.


Originating as a UK CRO company, we work on an international scale and are currently supporting Phase I-IV clinical trials across:

4
Continents
38
Countries
400
Employees with international reach

Let’s collaborate

If you think we could be right for you, get in touch.

Submit an RFI/RFP

The people working at Simbec Orion are dedicated, very professional and they cover all aspects of clinical research. A team will be set up for your project, who will have a strong focus on your study in a very open minded and friendly atmosphere. The studies I have outsourced to Simbec Orion, have been successfully managed and performed. I will use Simbec Orion in the future and I can strongly recommend them to other pharmaceutical companies.

Tina Lidén Mascher, Head of Clinical Operations Klaria AB

In these exceptional circumstances regulators are accelerating approval to support COVID-19 clinical research. Contact us today to find out more.